Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for BeiGene, Ltd. (BGNE : NSDQ)
 
 • Company Description   
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.

Number of Employees: 8,200

 
 • Price / Volume Information   
Yesterday's Closing Price: $137.32 Daily Weekly Monthly
20 Day Moving Average: 303,883 shares
Shares Outstanding: 102.71 (millions)
Market Capitalization: $14,103.62 (millions)
Beta: 0.85
52 Week High: $426.56
52 Week Low: $120.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.16% -8.20%
12 Week -35.87% -27.92%
Year To Date -49.31% -38.08%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
94 SOLARIS AVENUE CAMANA BAY
-
GRAND CAYMAN,E9 KY1-1108
CYM
ph: 1-345-949-4123
fax: -
ir@beigene.com http://www.beigene.com
 
 • General Corporate Information   
Officers
John V. Oyler - Chief Executive Officer and Chairman
Julia Wang - Chief Financial Officer
Timothy Chen - Director
Donald W. Glazer - Director
Margaret Dugan - Director

Peer Information
BeiGene, Ltd. (CORR.)
BeiGene, Ltd. (RSPI)
BeiGene, Ltd. (CGXP)
BeiGene, Ltd. (BGEN)
BeiGene, Ltd. (GTBP)
BeiGene, Ltd. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 07725L102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 102.71
Most Recent Split Date: (:1)
Beta: 0.85
Market Capitalization: $14,103.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-4.38 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-15.13 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.39
Price/Cash Flow: -
Price / Sales: 16.08
EPS Growth
vs. Year Ago Period: -714.49%
vs. Previous Quarter: 31.17%
Sales Growth
vs. Year Ago Period: -49.39%
vs. Previous Quarter: 43.30%
ROE
03/31/22 - -40.10
12/31/21 - -32.85
09/30/21 - -35.06
ROA
03/31/22 - -27.86
12/31/21 - -22.36
09/30/21 - -23.40
Current Ratio
03/31/22 - 5.05
12/31/21 - 4.76
09/30/21 - 3.40
Quick Ratio
03/31/22 - 4.87
12/31/21 - 4.61
09/30/21 - 3.28
Operating Margin
03/31/22 - -218.25
12/31/21 - -120.15
09/30/21 - -122.41
Net Margin
03/31/22 - -218.25
12/31/21 - -120.15
09/30/21 - -122.41
Pre-Tax Margin
03/31/22 - -219.11
12/31/21 - -122.30
09/30/21 - -125.54
Book Value
03/31/22 - 57.34
12/31/21 - 60.95
09/30/21 - 35.97
Inventory Turnover
03/31/22 - 1.04
12/31/21 - 1.13
09/30/21 - 1.28
Debt-to-Equity
03/31/22 - 0.03
12/31/21 - 0.03
09/30/21 - 0.06
Debt-to-Capital
03/31/22 - 3.31
12/31/21 - 3.14
09/30/21 - 5.65
 

Powered by Zacks Investment Research ©